NCT07449858Active, not recruiting
18F-FDG PET/CT Radiomics Models for Precision Diagnosis and Prognosis in NSCLC
Construction and Validation of Precision Diagnosis and Treatment Models for Non-Small Cell Lung Cancer (NSCLC) Based on 18F-FDG PET/CT Radiomics: A Multicenter Retrospective Clinical Study
Source: ClinicalTrials.gov · Last updated 4 Mar 2026
Brief summary (registry, in English)
This multicenter retrospective study aims to investigate the value of 18F-FDG PET/CT radiomics features in the preoperative precision staging, pathological typing, gene mutation status prediction, and prognostic risk stratification of patients with Non-Small Cell Lung Cancer (NSCLC). The study involves constructing and validating machine learning models to provide imaging-based evidence for individualized precision clinical decision-making.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 26 Feb 2026
- Start date
- 1 Jul 2025
- Primary completion date
- 1 Mar 2026
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Diseases
- Lung cancer
- NCT number
- NCT07449858
What you commit to
- Study type: Observational
- Planned participants: 500
- From 1 Jul 2025 to the primary completion date, 1 Mar 2026
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received any anti-tumor treatment (chemotherapy, radiotherapy, targeted therapy, immunotherapy) prior to PET/CT.
Other illness
- History of other malignancies.
Other
- Severe image artifacts or indistinct tumor boundaries affecting ROI delineation.
- Missing key clinical or pathological data.
- Baseline PET/CT evaluated recurrent or metastatic tumors instead of primary NSCLC.
- Extremely short life expectancy due to severe comorbidities.
Who the study is looking for
- Age \>= 18 years.
- Underwent standard whole-body 18F-FDG PET/CT scan within 30 days before surgery.
- Histopathologically confirmed Non-Small Cell Lung Cancer (NSCLC) with clear histological subtyping and complete postoperative TNM staging.
- Primary tumor SUVmax \> 2.5 and maximum diameter \> 1.0 cm on CT.
- Complete clinical, pathological, and imaging data available.
- (For Gene Sub-study) Known EGFR gene mutation status.
- (For Prognosis Sub-study) Complete follow-up data available (minimum 12 months or until endpoint event).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| West China Hospital of Sichuan University Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
| Guangdong Second Provincial General Hospital Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| The Second Affiliated Hospital Zhejiang University School of Medicine Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
| The First Hospital of China Medical University Coordinator of this site? Confirm its status | Shenyang | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.